BR112015024060A2 - composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto - Google Patents
composto, composição farmacêutica, método para o tratamento de doenças e uso de um compostoInfo
- Publication number
- BR112015024060A2 BR112015024060A2 BR112015024060A BR112015024060A BR112015024060A2 BR 112015024060 A2 BR112015024060 A2 BR 112015024060A2 BR 112015024060 A BR112015024060 A BR 112015024060A BR 112015024060 A BR112015024060 A BR 112015024060A BR 112015024060 A2 BR112015024060 A2 BR 112015024060A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- treating diseases
- formula
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108091005482 5-HT4 receptors Proteins 0.000 abstract 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2013/000639 WO2014147636A1 (en) | 2013-03-20 | 2013-10-18 | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists |
| IN1199CH2013 IN2013CH01199A (zh) | 2013-03-20 | 2013-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015024060A2 true BR112015024060A2 (pt) | 2017-07-18 |
Family
ID=54325095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015024060A BR112015024060A2 (pt) | 2013-03-20 | 2013-10-18 | composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9790211B2 (zh) |
| EP (1) | EP2976337B1 (zh) |
| JP (1) | JP6185650B2 (zh) |
| KR (1) | KR101815307B1 (zh) |
| CN (1) | CN105164119B (zh) |
| AP (1) | AP2015008742A0 (zh) |
| AU (1) | AU2013382944B2 (zh) |
| BR (1) | BR112015024060A2 (zh) |
| CA (1) | CA2907620C (zh) |
| DK (1) | DK2976337T3 (zh) |
| EA (1) | EA029365B1 (zh) |
| ES (1) | ES2674993T3 (zh) |
| HK (1) | HK1217483A1 (zh) |
| IN (1) | IN2013CH01199A (zh) |
| MX (1) | MX364929B (zh) |
| NZ (1) | NZ712369A (zh) |
| SG (1) | SG11201507763RA (zh) |
| WO (1) | WO2014147636A1 (zh) |
| ZA (1) | ZA201506804B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59066B1 (sr) * | 2015-02-13 | 2019-09-30 | Suven Life Sciences Ltd | Jedinjenja amida kao agonisti 5-ht4 receptora |
| CN109444301A (zh) * | 2018-12-18 | 2019-03-08 | 江苏省中医院 | 一种测定血浆中普芦卡必利浓度的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0664805A1 (en) * | 1992-10-13 | 1995-08-02 | Smithkline Beecham Plc | Heterocyclic -esters or -amides used as 5-ht 4? receptor antagonists |
| CA2148700A1 (en) | 1992-11-05 | 1994-05-11 | Laramie Mary Gaster | Piperidine derivatives as 5-ht4 receptor antagonists |
| FR2756564B1 (fr) * | 1996-12-04 | 2004-05-14 | Synthelabo | Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique |
| WO2001095902A1 (en) * | 2000-06-15 | 2001-12-20 | Respiratorius Ab | A composition comprising a combination of receptor agonists and antagonists |
| CA2528656C (en) * | 2003-06-19 | 2012-01-03 | Janssen Pharmaceutica N.V. | 5ht4-antagonistic 4-(aminomethyl)-piperidine benzamides |
| ATE461192T1 (de) | 2003-11-24 | 2010-04-15 | Pfizer | Chinoloncarbonsäureverbindungen mit 5-ht4- rezeptoragonistischer wirkung |
| WO2005061483A2 (en) * | 2003-12-23 | 2005-07-07 | Bio-Medisinsk Innovasjon As | Modulators of peripheral 5-ht receptors |
| WO2005092882A1 (en) * | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| DK1856114T3 (en) | 2005-02-25 | 2014-11-17 | Raqualia Pharma Inc | Benzisoxazol-DERIVATIVES |
| EP1910340B1 (en) | 2005-07-22 | 2009-11-18 | Pfizer, Inc. | Indazolecarboxamide derivatives as 5ht4 receptor agonists |
| GB0525661D0 (en) * | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Novel compounds |
| CA2789663C (en) * | 2010-02-12 | 2018-10-02 | Raqualia Pharma Inc. | 5-ht4 receptor agonists for the treatment of dementia |
| IN2012DN06631A (zh) | 2010-02-16 | 2015-10-23 | Pfizer |
-
2013
- 2013-10-18 AP AP2015008742A patent/AP2015008742A0/xx unknown
- 2013-10-18 NZ NZ712369A patent/NZ712369A/en not_active IP Right Cessation
- 2013-10-18 CA CA2907620A patent/CA2907620C/en not_active Expired - Fee Related
- 2013-10-18 JP JP2016504852A patent/JP6185650B2/ja not_active Expired - Fee Related
- 2013-10-18 AU AU2013382944A patent/AU2013382944B2/en not_active Ceased
- 2013-10-18 MX MX2015012350A patent/MX364929B/es active IP Right Grant
- 2013-10-18 KR KR1020157030158A patent/KR101815307B1/ko active IP Right Grant
- 2013-10-18 CN CN201380074877.9A patent/CN105164119B/zh not_active Expired - Fee Related
- 2013-10-18 EA EA201591844A patent/EA029365B1/ru not_active IP Right Cessation
- 2013-10-18 DK DK13811624.9T patent/DK2976337T3/en active
- 2013-10-18 SG SG11201507763RA patent/SG11201507763RA/en unknown
- 2013-10-18 US US14/777,925 patent/US9790211B2/en not_active Expired - Fee Related
- 2013-10-18 BR BR112015024060A patent/BR112015024060A2/pt not_active IP Right Cessation
- 2013-10-18 ES ES13811624.9T patent/ES2674993T3/es active Active
- 2013-10-18 IN IN1199CH2013 patent/IN2013CH01199A/en unknown
- 2013-10-18 WO PCT/IN2013/000639 patent/WO2014147636A1/en active Application Filing
- 2013-10-18 EP EP13811624.9A patent/EP2976337B1/en active Active
-
2015
- 2015-09-14 ZA ZA2015/06804A patent/ZA201506804B/en unknown
-
2016
- 2016-05-12 HK HK16105434.5A patent/HK1217483A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR101815307B1 (ko) | 2018-01-04 |
| JP2016516089A (ja) | 2016-06-02 |
| HK1217483A1 (zh) | 2017-01-13 |
| MX2015012350A (es) | 2016-05-09 |
| AU2013382944A1 (en) | 2015-10-08 |
| ZA201506804B (en) | 2016-07-27 |
| EP2976337B1 (en) | 2018-05-02 |
| WO2014147636A1 (en) | 2014-09-25 |
| US9790211B2 (en) | 2017-10-17 |
| IN2013CH01199A (zh) | 2015-08-14 |
| CN105164119A (zh) | 2015-12-16 |
| NZ712369A (en) | 2016-11-25 |
| EP2976337A1 (en) | 2016-01-27 |
| DK2976337T3 (en) | 2018-07-16 |
| ES2674993T3 (es) | 2018-07-05 |
| CN105164119B (zh) | 2017-12-08 |
| AP2015008742A0 (en) | 2015-09-30 |
| EA201591844A1 (ru) | 2016-08-31 |
| KR20160004274A (ko) | 2016-01-12 |
| US20160280694A1 (en) | 2016-09-29 |
| JP6185650B2 (ja) | 2017-08-23 |
| EA029365B1 (ru) | 2018-03-30 |
| SG11201507763RA (en) | 2015-10-29 |
| CA2907620A1 (en) | 2014-09-25 |
| CA2907620C (en) | 2018-03-13 |
| MX364929B (es) | 2019-05-14 |
| WO2014147636A8 (en) | 2014-12-04 |
| AU2013382944B2 (en) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| EA201591339A1 (ru) | Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы | |
| BR112016017996A2 (pt) | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso | |
| BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
| BR112015014222A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica | |
| BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
| BR112014014452A2 (pt) | derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| BR112014031091A2 (pt) | Derivados de piperidina para agonista de gpr119 | |
| EA201690888A1 (ru) | Новые гетероциклические соединения | |
| BR112016011170A8 (pt) | derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica | |
| EA201600337A1 (ru) | 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний | |
| BR112017004589A2 (pt) | composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd | |
| BR112014029439A2 (pt) | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| BR112013017362A2 (pt) | composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores | |
| BR112018001035A2 (pt) | compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos | |
| BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |